Barclays PLC Celldex Therapeutics, Inc. Transaction History

Barclays PLC

$353 Billion
Q1 2025

A detailed history of Barclays PLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 116,566 shares of CLDX stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

116,566

Previous 142,914 18.44%

Holding current value

$2.28 Million

Previous $3.61 Million 41.43%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$18.15 - $27.6 $478,216 - $727,204	-26,348 Reduced 18.44%	116,566 $2.12 Million
Q4 2024 Feb 13, 2025	BUY	$23.31 - $32.4 $292,144 - $406,069	12,533 Added 9.61%	142,914 $3.61 Million
Q3 2024 Nov 15, 2024	BUY	$32.06 - $44.56 $2.44 Million - $3.4 Million	76,207 Added 140.67%	130,381 $4.43 Million
Q2 2024 Aug 14, 2024	SELL	$32.76 - $42.56 $410,810 - $533,702	-12,540 Reduced 18.8%	54,174 $2 Million
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $2.79 Million - $4.11 Million	-79,180 Reduced 54.27%	66,714 $2.8 Million
Q4 2023 Feb 15, 2024	BUY	$22.61 - $40.65 $54,964 - $98,820	2,431 Added 1.69%	145,894 $5.79 Million
Q3 2023 Nov 07, 2023	SELL	$25.45 - $37.46 $729,676 - $1.07 Million	-28,671 Reduced 16.66%	143,463 $3.95 Million
Q2 2023 Aug 03, 2023	BUY	$30.29 - $38.28 $1.91 Million - $2.42 Million	63,110 Added 57.89%	172,134 $5.84 Million
Q1 2023 May 04, 2023	SELL	$34.78 - $47.43 $259,006 - $353,211	-7,447 Reduced 6.39%	109,024 $3.92 Million
Q4 2022 Feb 13, 2023	SELL	$27.78 - $45.38 $781,062 - $1.28 Million	-28,116 Reduced 19.45%	116,471 $5.19 Million
Q3 2022 Nov 03, 2022	BUY	$22.7 - $37.57 $1.08 Million - $1.78 Million	47,500 Added 48.93%	144,587 $4.06 Million
Q2 2022 Aug 12, 2022	SELL	$20.5 - $37.33 $2.25 Million - $4.09 Million	-109,613 Reduced 53.03%	97,087 $2.62 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $1.84 Million - $2.62 Million	66,748 Added 47.69%	206,700 $7.04 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $3.57 Million - $5.64 Million	100,184 Added 251.92%	139,952 $5.41 Million
Q3 2021 Nov 09, 2021	BUY	$28.95 - $55.99 $519,449 - $1 Million	17,943 Added 82.21%	39,768 $2.15 Million
Q2 2021 Aug 13, 2021	SELL	$20.71 - $35.37 $693,246 - $1.18 Million	-33,474 Reduced 60.53%	21,825 $730,000
Q1 2021 May 13, 2021	BUY	$16.19 - $29.91 $887,195 - $1.64 Million	54,799 Added 10959.8%	55,299 $1.14 Million
Q4 2020 Feb 11, 2021	SELL	$14.99 - $22.75 $5,486 - $8,326	-366 Reduced 42.26%	500 $9,000
Q3 2020 Nov 12, 2020	BUY	$9.65 - $15.19 $8,337 - $13,124	864 Added 43200.0%	866 $13,000
Q2 2020 Aug 12, 2020	BUY	$1.61 - $13.41 $3 - $26	2 New	2 $0
Q4 2019 Feb 10, 2020	SELL	$2.11 - $2.8 $54 - $72	-26 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.05 - $2.75 $7,994 - $10,725	-3,900 Reduced 99.34%	26 $0
Q2 2019 Aug 14, 2019	SELL	$2.43 - $5.09 $12,636 - $26,468	-5,200 Reduced 56.98%	3,926 $10,000
Q1 2019 May 15, 2019	BUY	$3.45 - $10.35 $31,484 - $94,454	9,126 New	9,126 $45,000

Others Institutions Holding CLDX

# of Institutions

188

Shares Held

69.3M

Call Options Held

220K

Put Options Held

310K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $913M
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account